 Drug Design
"Drug Design" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
| Descriptor ID |
D015195
|
| MeSH Number(s) |
E05.295.500 H01.158.703.007.675.500 H01.181.466.675.500
|
| Concept/Terms |
Drug Design- Drug Design
- Design, Drug
- Designs, Drug
- Drug Designs
Drug Modeling- Drug Modeling
- Drug Modelings
- Modeling, Drug
- Modelings, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Design".
Below are MeSH descriptors whose meaning is more specific than "Drug Design".
This graph shows the total number of publications written about "Drug Design" by people in this website by year, and whether "Drug Design" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 1 | 1 | | 1993 | 1 | 1 | 2 | | 1995 | 2 | 3 | 5 | | 1998 | 1 | 1 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 1 | 1 | 2 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 4 | 5 | | 2004 | 1 | 3 | 4 | | 2005 | 3 | 3 | 6 | | 2006 | 1 | 4 | 5 | | 2007 | 2 | 4 | 6 | | 2008 | 3 | 9 | 12 | | 2009 | 1 | 5 | 6 | | 2010 | 5 | 4 | 9 | | 2011 | 6 | 5 | 11 | | 2012 | 6 | 8 | 14 | | 2013 | 3 | 9 | 12 | | 2014 | 1 | 2 | 3 | | 2015 | 2 | 1 | 3 | | 2016 | 3 | 2 | 5 | | 2017 | 1 | 5 | 6 | | 2018 | 2 | 2 | 4 | | 2019 | 0 | 6 | 6 | | 2020 | 2 | 0 | 2 | | 2021 | 1 | 3 | 4 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Design" by people in Profiles.
-
Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022 03 10; 65(5):3943-3961.
-
Sarkar A, Kim EY, Jang T, Hongdusit A, Kim H, Choi JM, Fox JM. Microbially Guided Discovery and Biosynthesis of Biologically Active Natural Products. ACS Synth Biol. 2021 06 18; 10(6):1505-1519.
-
Rogawski DS, Deng J, Li H, Miao H, Borkin D, Purohit T, Song J, Chase J, Li S, Ndoj J, Klossowski S, Kim E, Mao F, Zhou B, Ropa J, Krotoska MZ, Jin Z, Ernst P, Feng X, Huang G, Nishioka K, Kelly S, He M, Wen B, Sun D, Muntean A, Dou Y, Maillard I, Cierpicki T, Grembecka J. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Nat Commun. 2021 05 14; 12(1):2792.
-
Eller KA, Aunins TR, Courtney CM, Campos JK, Otoupal PB, Erickson KE, Madinger NE, Chatterjee A. Facile accelerated specific therapeutic (FAST) platform develops antisense therapies to counter multidrug-resistant bacteria. Commun Biol. 2021 03 12; 4(1):331.
-
Kolaric A, Germe T, Hrast M, Stevenson CEM, Lawson DM, Burton NP, Vörös J, Maxwell A, Minovski N, Anderluh M. Potent DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds. Nat Commun. 2021 01 08; 12(1):150.
-
Rani A, Johansen MD, Roquet-Banères F, Kremer L, Awolade P, Ebenezer O, Singh P, Kumar V. Design and synthesis of 4-Aminoquinoline-isoindoline-dione-isoniazid triads as potential anti-mycobacterials. Bioorg Med Chem Lett. 2020 11 15; 30(22):127576.
-
Vann KR, Pal D, Morales GA, Burgoyne AM, Durden DL, Kutateladze TG. Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets. Sci Rep. 2020 07 21; 10(1):12027.
-
Rani A, Kumar S, Legac J, Adeniyi AA, Awolade P, Singh P, Rosenthal PJ, Kumar V. Design, synthesis, heme binding and density functional theory studies of isoindoline-dione-4-aminoquinolines as potential antiplasmodials. Future Med Chem. 2020 02; 12(3):193-205.
-
Cruz-Torres I, Backos DS, Herson PS. Characterization and Optimization of the Novel Transient Receptor Potential Melastatin 2 Antagonist tatM2NX. Mol Pharmacol. 2020 02; 97(2):102-111.
-
Abraham AD, Esquer H, Zhou Q, Tomlinson N, Hamill BD, Abbott JM, Li L, Pike LA, Rinaldetti S, Ramirez DA, Lunghofer PJ, Gomez JD, Schaack J, Nemkov T, D'Alessandro A, Hansen KC, Gustafson DL, Messersmith WA, LaBarbera DV. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. J Med Chem. 2019 11 27; 62(22):10182-10203.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|